Established in 1987 by the National Institute of Allergy and Infectious Diseases (NIAID), ACTG is the world’s largest and longest-running HIV clinical trials network. The ACTG conducts groundbreaking research to improve the treatment of HIV and its co-infections, including tuberculosis and viral hepatitis. The network’s studies have had a profound impact on the well-being of people living with HIV, helping to establish current paradigms for treating HIV and contributing to dramatic decreases in HIV-related mortality worldwide.

Frontier Science manages and analyzes the clinical and laboratory data collected by the ACTG network, and acts as liaison between study teams and clinical sites concerning all aspects of data required during an ACTG study.